Viracta Therapeutics (VIRX) Expected to Announce Quarterly Earnings on Thursday

Viracta Therapeutics (NASDAQ:VIRX) is projected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

Viracta Therapeutics Stock Performance

Shares of VIRX opened at $0.02 on Wednesday. The firm has a market cap of $894,240.00, a P/E ratio of -0.02 and a beta of 0.70. Viracta Therapeutics has a twelve month low of $0.01 and a twelve month high of $1.31. The firm’s 50 day moving average price is $0.11 and its two-hundred day moving average price is $0.18.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Rodman & Renshaw reaffirmed a “neutral” rating and issued a $0.25 price objective (down from $3.50) on shares of Viracta Therapeutics in a research report on Friday, December 27th. Royal Bank of Canada cut their price target on Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Viracta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.05.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.